This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

OncoMed Pharmaceuticals To Present Phase 1a Data In Advanced Solid Tumor Patients For The First-in-Class WNT-Pathway-Targeting Antibody Vantictumab (OMP-18R5) At The European Cancer Congress 2013 (ECC 2013)

Updated clinical data to be presented for vantictumab at ECC 2013

Vantictumab, a program partnered with Bayer Pharma AG, is advancing to three combination Phase 1b studies in selected tumor types

REDWOOD CITY, Calif., Sept. 23, 2013 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today reported that new data for vantictumab, a monoclonal antibody targeting the WNT pathway, will be presented at a poster session at the Joint ECCO 17, 38th ESMO and 32nd ESTRO European Cancer Congress 2013 (ECC 2013) in Amsterdam, The Netherlands.

The poster presentation called "A phase I study in patients with advanced solid tumors for the human monoclonal antibody vantictumab (OMP-18R5; anti-Frizzled) targeting the WNT pathway" will be presented in the Poster Session "Drug Development" on Sunday, September 29, 2013 from 09:30 to 12:00 CET. The presenting author is Dr. David Smith from the University of Michigan Cancer Center at Ann Arbor, MI, on behalf of the other principal investigators Dr. Lee Rosen at the University of California, Los Angeles, CA, Dr. Kyriakos Papadopoulos at The START Center for Cancer Care, San Antonio, TX and the entire study team.

Vantictumab is a first-in-class monoclonal antibody that has broad anti-cancer stem cell and anti-tumor activity in patient-derived xenograft tumor models. In the ongoing Phase 1a trial, vantictumab is well tolerated in advanced solid tumor patients. Vantictumab shows pharmacodynamic effects on the WNT pathway in patient samples. OncoMed is planning to initiate Phase 1b trials in three tumor indications to study its safety in combination with standard-of-care chemotherapy. Vantictumab is part of OncoMed's Wnt pathway collaboration with Bayer Pharma AG.

Paul Hastings, Chairman and Chief Executive Officer of OncoMed noted, "We have made excellent progress with vantictumab and our other clinical program targeting the WNT pathway, Fzd8-Fc (also known as OMP-54F28). We look forward to presenting the updated data for vantictumab in advanced solid tumor patients at the European Cancer Congress 2013 in Amsterdam."

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $95.03 -2.90%
FB $116.73 7.20%
GOOG $691.02 -2.10%
TSLA $247.54 -1.60%
YHOO $36.59 -0.97%


Chart of I:DJI
DOW 17,830.76 -210.79 -1.17%
S&P 500 2,075.81 -19.34 -0.92%
NASDAQ 4,805.2910 -57.85 -1.19%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs